PARP16 and cardiac hypertrophy: Collectively, these above results elucidated that PARP16 deficiency by gene delivery via AAV9 vector or lentivirus infection could ameliorate TAC- or Ang II infusion-induced cardiac hypertrophy or fibrosis and improve the cardiac function in vivo.